Intercontinental Wealth Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Intercontinental Wealth Advisors’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,967	Closed	-$49K	–	143
2016 Q3	$49K	Hold	4,967	–	–	0.03%	117
2016 Q2	$28K	Hold	4,967	–	–	0.02%	118
2016 Q1	$38K	Hold	4,967	–	–	0.03%	122
2015 Q4	$66K	Buy	+4,967	New	+$85.5K	0.05%	126

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Intercontinental Wealth Advisors's CASC Position: Q4 2016 in Review

Intercontinental Wealth Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 4,967 shares — an estimated $49K sold.

Intercontinental Wealth Advisors first reported a position in CASC in Q4 2015 and held it in 4 quarters. The position peaked at $66K in Q4 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

Intercontinental Wealth Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Intercontinental Wealth Advisors sold 4,967 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $49K.
Intercontinental Wealth Advisors first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 4 quarters.
Intercontinental Wealth Advisors's Cascadian Therapeutics, Inc. position peaked at $66K in Q4 2015.
57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on Intercontinental Wealth Advisors's 13F filing for Q4 2016, filed 9 Mar 2018.